نتایج جستجو برای: hpv vaccine

تعداد نتایج: 124304  

2018
Petra J Woestenberg Audrey J King Birgit H B van Benthem Robine Donken Suzan Leussink Fiona R M van der Klis Hester E de Melker Marianne A B van der Sande Christian J P A Hoebe Johannes A Bogaards D Adema R Buist-Arkema A Beerens D Luijt S Meijer J Schirm M Peeters J Rossen H Verbakel P van Esch J Verweij A van der Eijk R Huisman C Kerkhof H Korff M Schutten J Velzing F Verduyn-Lunel S Lakbiach P van Rosmalen R Schuurman D Abma K Adams S Bruisten I Linde P Oostvogel C Touwen W Vermeulen A Brink J Nelissen P Wolffs N Duijvendijk P Schneeberger M Dinnissen van Poppel W Melchers Y Poort M Hooghiemstra H Huisman J Weel F Bosma F Geeraedts I Polman P van Goor M Wolfhagen C de Mooij E van Koolwijk M Peters C Swanink R Tiemessen T van Zwet J Janssen M Pelsers W de Waal G Aalfs J Kiewiet P Sanders H van Buel-Bruins C van Bokhoven-Rombouts P Cornelissen M Kersten C van Ruitenbeek I Molenaar E Doorn L Masthoff E Pannekoek V Sigurdsson M Bugter H Götz M Illidge-Onder de Linden M Mattijssen J Stam E Swaders F de Groot F Postma E Brouwers A Niekamp M Smit A Botraby D Bukasa C de Haan P Hut-van Vliet T Taconis M de Graas I Hondelink C Kampman A Gelissen-Hansen I de Koning H van Kruchten M van de Pas H Fennema T Heijman A Hogewoning A van Leeuwen M van Rooijen F Neienhuijsen M Pelgrim

Background Observational postmarketing studies are important to assess vaccine effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and nonvaccine types in a high-risk population. Methods We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional survey in Dutch sexually transmitted infection ...

2016
Edward Kumakech Vanja Berggren Henry Wabinga Gabriella Lillsunde-Larsson Gisela Helenius Malin Kaliff Mats Karlsson Samuel Kirimunda Caroline Musubika Sören Andersson

The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (Cervarix®, GlaxoSmithKline, Belgium) pilot project in western Uganda. Cervical swabs were collecte...

Journal: :Journal of women's health 2008
Karah I Fazekas Noel T Brewer Jennifer S Smith

BACKGROUND Although cervical cancer rates in the United States are highest in Southern and rural areas, research on human papillomavirus (HPV) vaccine acceptability has focused on other geographic areas. METHODS To address this gap, we surveyed women from a rural area in North Carolina with elevated rates of cervical cancer to identify predictors of HPV vaccine acceptability for themselves an...

Journal: :The Journal of adolescent health : official publication of the Society for Adolescent Medicine 2010
Doris M Rivera Medina Alejandra Valencia Alet de Velasquez Li-Min Huang Roman Prymula Jose García-Sicilia Lars Rombo Marie Pierre P David Dominique Descamps Karin Hardt Gary Dubin

PURPOSE Immunization of girls against oncogenic human papillomavirus (HPV) types before sexual debut is important for cervical cancer prevention. This phase III blinded, randomized, controlled trial in adolescent girls assessed safety of the HPV-16/18 AS04-adjuvanted vaccine. METHODS Girls (mean age 12 years) in 12 countries received the HPV-16/18 L1 virus-like particle AS04-adjuvanted vaccin...

Journal: :Vaccine 2006
Loretta Brabin Stephen A Roberts Farah Farzaneh Henry C Kitchener

The main target group for vaccination against human papillomavirus (HPV), the sexually transmitted virus that causes cervical cancer, will be young adolescents. We undertook a population-based survey to assess parental consent and potential HPV vaccine uptake in eight secondary schools using stratified randomisation according to school type and ethnicity. Our results suggest that in socially an...

2012
Deborah Watson-Jones Keith Tomlin Pieter Remes Kathy Baisley Riziki Ponsiano Selephina Soteli Silvia de Sanjosé John Changalucha Saidi Kapiga Richard J. Hayes

BACKGROUND There are few data on factors influencing human papillomavirus (HPV) vaccination uptake in sub-Saharan Africa. We examined the characteristics of receivers and non-receivers of HPV vaccination in Tanzania and identified reasons for not receiving the vaccine. METHODS We conducted a case control study of HPV vaccine receivers and non-receivers within a phase IV cluster-randomised tri...

Journal: :Human vaccines & immunotherapeutics 2013
Annie-Laurie McRee Paul L Reiter Jessica K Pepper Noel T Brewer

Low uptake of human papillomavirus (HPV) vaccine calls for innovative approaches. Offering the vaccine in settings outside the traditional medical home, such as schools and pharmacies, could increase use. We sought to characterize the acceptability of HPV vaccine delivery in these alternative settings using a national (US) sample of parents of adolescent males ages 11-17 y (n = 506) and their s...

Journal: :Vaccine 2011
Jessica A Kadis Annie-Laurie McRee Sami L Gottlieb Morgan R Lee Paul L Reiter Patricia J Dittus Noel T Brewer

HPV vaccination rates among adolescents in the United States lag behind some other developed countries, many of which routinely offer the vaccine in schools. We sought to assess mothers' willingness to have their adolescent daughters receive HPV vaccine at school. A national sample of mothers of adolescent females ages 11-14 completed our internet survey (response rate=66%). The final sample (n...

2014
Wilson Winstons Muhwezi Cecily Banura Andrew Kampikaho Turiho Florence Mirembe

The Ministry of Health in Uganda in collaboration with the Program for Appropriate Technology for Health (PATH) supported by Bill and Melinda Gates Foundation in 2008-2009 vaccinated approximately 10,000 girls with the bivalent humanpapilloma virus (HPV) vaccine. We assessed parent's knowledge, risk perception and willingness to allow son(s) to receive HPV vaccines in future through a cross-sec...

Journal: :Gynecologic oncology 2014
Noel T Brewer Jake K Chung Hannah M Baker Mitchel C Rothholz Jennifer S Smith

OBJECTIVES While the provision of cervical cancer prevention services in the United States has expanded to new settings beyond clinics that give Pap smears, prevention efforts are being hampered by relatively low human papillomavirus (HPV) vaccine coverage. Pharmacies are an underused setting to deliver HPV vaccine. To better understand this opportunity, we sought to classify pharmacists' autho...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید